Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
p38 has been shown to be a critical enzyme in the pro-inflammatory cytokine pathway and is a member of the mitogen-activated protein (MAP) kinase family. While the details for p38 activation and subsequent signal transduction have begun to be elucidated, little is known about the kinetic mechanism for p38. In this study, we have determined the kinetic mechanism for p38 MAP kinase. Data from initial velocity patterns in the presence and absence of a dead-end inhibitor and two triarylimidazole p38 inhibitors were consistent with an ordered sequential mechanism for p38 with protein substrate, glutathione S-transferase-
activating transcription factor 2
(GST-ATF2), binding before ATP. The ATP analog, adenylyl methylenediphosphonate (AMP-
PCP
), and two triarylimidazoles were competitive inhibitors versus ATP and uncompetitive inhibitors versus GST-ATF2. Equilibrium binding studies utilizing a tritiated ATP-competitive inhibitor were also consistent with this mechanism and suggest an inability of ATP to bind to p38 in the absence of protein substrate. Moreover, the Michaelis constant for GST-ATF2 was 12-fold greater than the dissociation constant, indicating that the binding of ATP affected the binding of GST-ATF2. An ordered sequential mechanism with protein substrate binding first is unique to p38 compared to cyclic AMP-dependent protein kinase (cAPK) and most tyrosine kinases and helps to explain the interaction between enzyme, substrates, and inhibitors.
...
PMID:Kinetic mechanism for p38 MAP kinase. 926 22
c-jun-N-Terminal kinase 3alpha1 (JNK3alpha1) is a mitogen-activated protein (MAP) kinase family member expressed primarily in the brain that phosphorylates protein transcription factors including c-jun and
activating transcription factor 2
(
ATF2
) upon activation by a variety of stress-based stimuli. In this study, the kinetic mechanism for JNK3alpha1 was determined via initial velocity patterns in the presence and absence of both ATP and
ATF2
competitive inhibitors. Peptide inhibitors from both
ATF2
(peptide 1) and JNK-interacting protein 1 (JIP-1) (peptide 3), derived from the homologous delta-domain JNK docking sequence, inhibited JNK3alpha1 activity in a competitive fashion versus
ATF2
while being pure noncompetitive toward ATP. In contrast, peptides derived from the phosphoacceptor activation domain on
ATF2
(peptides 4 and 5) were recognized neither as substrates nor as inhibitors of JNK3alpha1. AMP-
PCP
and compound 6, a small molecule analinopyrimidine, exhibited pure noncompetitive inhibition versus
ATF2
and competitive inhibition versus ATP. Peptide inhibitors based on the delta-domain sites of JIP ( 3) and
ATF2
( 1) were not recognized by p38, also of the MAPK family, which may give insight into finding more selective inhibitors for the JNK family of kinases. Collectively these data showed that JNK3alpha1 proceeded by a random sequential kinetic mechanism and that the ATP and
ATF2
substrate sites were non-interacting. Moreover, these results established the 11-mer JIP peptide ( 3) as a potent ( K i = 25 +/- 6 nM) competitive inhibitor versus
ATF2
in JNK3alpha1.
...
PMID:Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1. 1826 48
c-jun-N-terminal kinase 1alpha1 (JNK1alpha1) is a serine/threonine kinase of the mitogen-activated protein (MAP) kinase family that phosphorylates protein transcription factors after activation by a variety of environmental stressors. In this study, the kinetic mechanism for JNK1alpha1 phosphorylation of
activating transcription factor 2
(
ATF2
) was determined utilizing steady-state kinetics in the presence and absence of both
ATF2
and ATP competitive inhibitors. Data from initial velocity studies were consistent with a sequential mechanism for JNK1alpha1. AMP-
PCP
exhibited competitive inhibition versus ATP and pure noncompetitive inhibition versus
ATF2
. JIP-1 peptide (RPKRPTTLNLF) was competitive versus
ATF2
and mixed noncompetitive versus ATP. These data suggest that JNK1alpha1 proceeded via a random sequential kinetic mechanism with non-interacting
ATF2
and ATP substrate sites.
...
PMID:Mechanistic characterization for c-jun-N-Terminal Kinase 1alpha1. 1855 53